UPDATE: See June 23, 2020 article here describing the notable changes. See our article here regarding the final October 2020 Guidelines. On November 23, Innovative Medicines Canada and a number of research-based pharmaceutical companies commenced an application for judicial review of the final Guidelines.
The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.
An industry webinar on the revised draft Guidelines is scheduled for June 29, 2020 from 1:30 – 4:30pm. A public webinar is scheduled for July 8, 2020 from 1:30 to 4:30pm.
The accompanying backgrounder document is to be released by the PMPRB the week of June 22.
Our more detailed reporting of the substantial changes to the first draft of the Guidelines, which were published in November of 2019, will soon follow (see here).
Should you have any questions on the foregoing, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB publishes annual Meds Pipeline Monitor report
The Patented Medicine Prices Review Board (PMPRB) recently published its Meds Pipeline Monitor 2022 report, which highlights medicines in the pipeline that may impact future clinical practice and drug...Read More -
Developments in time-limited pharmaceutical market access: pCPA Temporary Access Process
The pan-Canadian Pharmaceutical Alliance (pCPA) has recently released a set of principles and conditions for its Temporary Access Process (pTAP) to inform the negotiation process and potential product...Read More -
PMPRB news: New Vice Chairperson appointed, Meds Entry Watch 7th Ed. published
On August 15, 2023, the Minister of Health announced the appointment of Anie Perrault as Vice Chairperson of the Patented Medicine Prices Review Board (PMPRB) for a five-year term.Read More